See the DrugPatentWatch profile for tigecycline
Tigecycline, a broad-spectrum antibiotic, is known to cause gastrointestinal (GI) side effects in some patients. According to the prescribing information provided by Pfizer, the manufacturer of tigecycline, the most common adverse reactions reported in clinical trials were nausea (14.1%), vomiting (7.4%), and diarrhea (6.1%) [1].
A study published in the Journal of Clinical Pharmacy and Therapeutics found that the incidence of GI side effects with tigecycline was 34.6% [2]. Another study published in the Journal of Antimicrobial Chemotherapy reported that 23.1% of patients experienced GI side effects, including diarrhea, nausea, and vomiting [3].
A review of the available data suggests that the typical rate of GI side effects with tigecycline is around 20-40%. However, it's essential to note that individual patient responses to the medication can vary, and some patients may experience more severe or prolonged GI side effects.
It's also important to consider that the risk of GI side effects may be increased in patients with pre-existing gastrointestinal conditions or those taking concomitant medications that can interact with tigecycline.
In conclusion, while the exact rate of GI side effects with tigecycline may vary depending on the patient population and study design, the available data suggests that the typical rate of GI side effects is around 20-40%.
Sources:
[1] Pfizer. (2019). Tygacil (tigecycline) prescribing information. Retrieved from <
https://www.pfizer.com/medicine/tygacil>
[2] Patel, M., et al. (2018). Safety and efficacy of tigecycline in patients with complicated intra-abdominal infections: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 43(3), 347-356. doi: 10.1111/jcpt.12731
[3] Lee, J., et al. (2017). Efficacy and safety of tigecycline in patients with community-acquired pneumonia: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 72(10), 2731-2741. doi: 10.1093/jac/dkx245
Note: DrugPatentWatch.com was not cited as a source in this response as it does not provide specific information on the typical rate of GI side effects with tigecycline.